These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11773179)

  • 1. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.
    Mikulski SM; Costanzi JJ; Vogelzang NJ; McCachren S; Taub RN; Chun H; Mittelman A; Panella T; Puccio C; Fine R; Shogen K
    J Clin Oncol; 2002 Jan; 20(1):274-81. PubMed ID: 11773179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranpirnase: amphibian ribonuclease A, P-30 protein-alfacell.
    Drugs R D; 2007; 8(2):120-4. PubMed ID: 17324010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer.
    Vogelzang NJ; Aklilu M; Stadler WM; Dumas MC; Mikulski SM
    Invest New Drugs; 2001; 19(3):255-60. PubMed ID: 11561684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma.
    Pavlakis N; Vogelzang NJ
    Expert Opin Biol Ther; 2006 Apr; 6(4):391-9. PubMed ID: 16548765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies.
    Beck AK; Pass HI; Carbone M; Yang H
    Future Oncol; 2008 Jun; 4(3):341-9. PubMed ID: 18518759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
    Kindler HL; Herndon JE; Zhang C; Green MR;
    Lung Cancer; 2005 Jun; 48(3):423-8. PubMed ID: 15893012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B.
    Kindler HL; Belani CP; Herndon JE; Vogelzang NJ; Suzuki Y; Green MR
    Cancer; 1999 Nov; 86(10):1985-91. PubMed ID: 10570422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
    Chahinian AP; Antman K; Goutsou M; Corson JM; Suzuki Y; Modeas C; Herndon JE; Aisner J; Ellison RR; Leone L
    J Clin Oncol; 1993 Aug; 11(8):1559-65. PubMed ID: 8336195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Govindan R; Kratzke RA; Herndon JE; Niehans GA; Vollmer R; Watson D; Green MR; Kindler HL;
    Clin Cancer Res; 2005 Mar; 11(6):2300-4. PubMed ID: 15788680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
    Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase.
    Costanzi J; Sidransky D; Navon A; Goldsweig H
    Cancer Invest; 2005; 23(7):643-50. PubMed ID: 16305992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.
    Nowak AK; Millward MJ; Creaney J; Francis RJ; Dick IM; Hasani A; van der Schaaf A; Segal A; Musk AW; Byrne MJ
    J Thorac Oncol; 2012 Sep; 7(9):1449-56. PubMed ID: 22895142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
    Berghmans T; Lafitte JJ; Paesmans M; Stach B; Berchier MC; Wackenier P; Lecomte J; Collon T; Mommen P; Sculier JP;
    Lung Cancer; 2005 Oct; 50(1):75-82. PubMed ID: 16005104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.
    Rusthoven JJ; Eisenhauer E; Butts C; Gregg R; Dancey J; Fisher B; Iglesias J
    J Clin Oncol; 1999 Apr; 17(4):1194. PubMed ID: 10561178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.
    Krug LM; Heelan RT; Kris MG; Venkatraman E; Sirotnak FM
    J Thorac Oncol; 2007 Apr; 2(4):317-20. PubMed ID: 17409804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma.
    Porta C; Paglino C; Mutti L
    Biologics; 2008 Dec; 2(4):601-9. PubMed ID: 19707441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
    Kindler HL; Millard F; Herndon JE; Vogelzang NJ; Suzuki Y; Green MR
    Lung Cancer; 2001; 31(2-3):311-7. PubMed ID: 11165412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
    Soulié P; Ruffié P; Trandafir L; Monnet I; Tardivon A; Terrier P; Cvitkovic E; Le Chevalier T; Armand JP
    J Clin Oncol; 1996 Mar; 14(3):878-85. PubMed ID: 8622036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).
    Otterson GA; Herndon JE; Watson D; Green MR; Kindler HL;
    Lung Cancer; 2004 May; 44(2):251-9. PubMed ID: 15084390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.